AGA living guideline recommends patients start advanced therapies early in their disease course rather than gradual step-up treatment approach. “Since the first biologic treatment for ulcerative ...
New research reveals a lack of consensus in defining moderate Crohn’s disease and ulcerative colitis, limiting optimal ...
Ferring Pharmaceuticals today announces results from the OPTIMISE study showing the first real-world evidence of the effectiveness of a treat-to-target (T2T) approach based on faecal calprotectin (FC) ...
Takeda presented promising data on its ulcerative colitis and Crohn’s disease drug Entyvio at the World Congress of Gastroenterology at ACG2017, Oct. 13 to Oct. 18 in Orlando, Fla. The data suggests ...
Moderate-to-severe disability affects nearly one-third of patients with inflammatory bowel disease (IBD), according to a ...
-PK/PD confirm results seen in healthy volunteer studies, with median RO >99% and saturation achieved early and sustained at week 12- WALTHAM, Mass., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Morphic ...
Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate response to either conventional treatment options or tumor necrosis factor ...
Spyre Therapeutics' stock rises 73% in a month after mid-stage data show strong efficacy and safety for SPY001 in ulcerative ...
Intestinal ultrasound (IUS) is non-invasive, cost-effective, and accurate to determine disease activity in ulcerative colitis (UC). In this study, we prospectively evaluated IUS for treatment response ...
Bethesda, MD (Nov. 15, 2024) — The American Gastroenterological Association (AGA) has released a new clinical guideline on the pharmacological management of moderate-to-severe ulcerative colitis, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results